Rusfertide: Regulatory submission in US for polycythemia Vera (based on VERIFY trial) in Q4 2025 (Protagonist Therapeutics) - Feb 19, 2025 - Corporate Presentation
FDA filing • Hematological Malignancies • Myeloproliferative Neoplasm • Oncology • Polycythemia Vera
|